Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Skyworks Solutions Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Skyworks Solutions Inc trades at $76.65 (market cap $12.15B). The key difference: Halozyme Therapeutics Inc. Common Stock and Skyworks Solutions Inc are close in size by market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Skyworks Solutions Inc for 50 Days on average.
| HALO | SWKS | |
|---|---|---|
Market Cap | $12.58B | $12.15B |
Volume | 2,179,278 | 7,390,810 |
Sector | Health | Technology |
52-Week High | $115.22 | $91.45 |
52-Week Low | $61.63 | $52.50 |
Typical Hold Time | 1 Days | 50 Days |
Enterprise Value | $14.49B | $12.03B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Skyworks Solutions (SWKS) trades at $76.35, down 8.49% in the last session, reflecting near-term pressure despite beating earnings estimates in recent quarters. The stock exhibits a bearish technical signal, with key support at $76, while fundamentals show declining revenue and net income margins over recent years. The pending merger with Qorvo represents a significant strategic development, aimed at enhancing scale and market diversification.
The investment outlook is mixed, with analyst consensus leaning bullish (60% buy ratings) and a price target of $78.80 offering modest upside. However, risks include execution challenges from the merger, competitive pressures in semiconductors, and ongoing profitability declines. The stock's current valuation at a P/E of 41.84 appears elevated relative to earnings growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
